Cancer Therapy

Updated phase II lung cancer clinical trial results presented at ASCO

Published in Cancer Weekly, July 6th, 2004

Genaera Corp. (GENR) announced updated interim safety and efficacy results for its antiangiogenic drug, squalamine, in its phase IIb non-small cell lung cancer (NSCLC) clinical trial.

The presentation was made at the 40th annual meeting of the American Society of Clinical Oncology (ASCO), held in New Orleans, Louisiana.

This multicenter, randomized study enrolled 45 stage IIIb or stage IV advanced lung cancer patients who were to receive weekly dosing of squalamine, combined with weekly chemotherapy of carboplatin and paclitaxel. All 45 patients were evaluated for safety. Overall, the combined drug regimen was well-tolerated, with fewer serious...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry